Our Story: Turning market potential into reality

Mr. Romp has over 25 years of experience building the pharmaceutical commercialization process from development stage to successful global product. As Executive Vice President, US Commercial for Seagen, Inc., prior to the company’s acquisition by Pfizer, Mr. Romp oversaw the entire Seagen Commercial organization in addition to broader roles in corporate communications, investor relations, and business development as a member of the executive committee. Previously, he spent 12 years at Genentech in a wide range of sales, marketing, and development roles spanning their entire oncology and immunology product portfolio. Mr. Romp has an extensive background in various therapeutic areas with an emphasis on oncology and hematology.

Mr. Brown has deep experience in capital markets, accounting, and finance. He formerly was the Chief Financial Officer and Interim Chief Executive Officer of ObsEva SA, where he led the company through a restructuring, successfully generating a strategic disposition valued higher than $100 million. He also served as the Chief Financial Officer of Altimmune, Inc., where he was critical in the transformation and growth of the company through more than $300 million of new equity issuances and a strategic acquisition. Mr. Brown was a consultant to private and public companies in a variety of accounting and financial matters as managing partner of Redmont Advisors and CPAs. Mr. Brown was a CPA (2006 to 2022, AL# 10198), and earned both his MBA and B.S. from Auburn University Montgomery.

Dr. Estruch co-founded Secura Bio after serving in several senior roles, including Head of Corporate Development, at Ciba-Geigy, Novartis, Diversa, Prometheus, and Genoptix. He has over 25 years of experience in life sciences and extensive experience in product assessment, corporate strategy, and corporate development. Dr. Estruch has a proven track record of identifying under-exploited biopharmaceutical assets that are candidates for repositioning or relaunch. Dr. Estruch earned a Ph.D. in biochemistry and molecular biology from the University of Essen, Germany and Valencia, Spain. He also earned an MBA from the Fuqua School of Business, Duke University.

Mr. Wessels has over 25 years of life sciences experience in sales, marketing, and commercialization strategy, most recently having served as Senior Vice President and Chief Commercial Officer of Aprea Therapeutics. Mr. Wessels also held global and regional positions of increasing responsibility over more than 10 years at Celgene Corporation, primarily in hematology and oncology, culminating as Executive Director, Lymphoma Global Marketing. Prior to joining Celgene, he spent 11 years with Sanofi US in sales, marketing, and business planning roles. Mr. Wessels received a B.S. in biochemistry from the University of Notre Dame and an MBA from the Kellogg School of Management at Northwestern University.

Dr. Langer holds more than 20 years of clinical research and medical affairs experience, most recently having served as Senior Vice President, Global Medical Affairs at BeiGene and before that Senior Vice President, Global Medical Affairs for Atara Biotherapeutics and Vice President of Global Medical Affairs for Agios Pharmaceuticals. She also held senior medical positions for Roche/Genentech in both the U.S. and Germany. In these roles, she built and managed medical affairs teams, led successful launches, nurtured strong relationships in the scientific community with professional societies, cooperative and patient advocacy groups and established deep expertise around cell therapies and various hematology- and oncology-related indications. Prior to these positions, Dr. Langer held positions of increasing responsibility within clinical development at Bristol Myers Squibb in the U.S. and Europe.

Dr. Langer earned her medical degree from the University of Freiburg, Germany, and spent her residency in obstetrics and gynecology with a focus on gynecologic oncology at the University Hospital Hannover, Germany. She completed postdoctoral studies on apoptosis in breast cancer under Dr. John Reed at the Burnham Institute in La Jolla, California.

Cari Barthe is a Human Resources Professional with over 25 years of experience and a deep understanding of biotech business and organizational needs, having spent a majority of her career in the sector. Prior to Secura Bio, Barthe served as Director of People and Culture, US at Notch Therapeutics. She has a proven track record of leading HR initiatives, recruiting excellent talent, improving department efficiencies and driving strategic business initiatives. Barthe is committed to collaboration and is passionate about building strong relationships and creating and fostering a culture of trust, respect, and high job satisfaction.